Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-2329 in Advanced Solid Tumors with RAS Mutations
NCT07189949Phase 1Recruiting
- Sponsor
- Hengrui
- Start
- Oct 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS-2329 in solid tumor (advanced stage), sponsored by Hengrui. Primary endpoints: Adverse Events, Serious Adverse Events and 3 more. Started Oct 2025; status: recruiting.
02
Drugs
HRS-2329
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07189949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07189949.